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ABSTRACT 
 
Understanding the functional sequelae of missense amino acid 
replacements is of fundamental importance in medical genetics. 
Perhaps the most intuitive way to assess the potential pathogenicity 
of a given human missense mutation is by measuring the degree of 
evolutionary conservation of the substituted amino acid residue, a 
feature which should in theory begenerally serves as a good proxy 
metric for the functional/structural importance of that residue. 
However, the presence of putative compensated mutations as the 
wild-type alleles in orthologous proteins of other mammalian 
species not only challenges this classical view of amino acid 
essentiality but also precludes the accurate evaluation of the 
functional impact of this ese type of missense mutations using 
existing currently available bioinformatic prediction tools. 
Compensated mutations constitute at least 4% of all known 
missense mutations causing human inherited disease and hence 
represent an important potential source of error in that they may 
often be misclassified as benign variants. The consequent under-
reporting of compensated mutations is exacerbated in the context 
3 
of next generation sequencing where their inappropriate exclusion 
constitutes an unfortunate natural consequence of the filtering and 
prioritization of the very large numbers of variants generated. Here 
we demonstrate the reduced performance of currently available 
pathogenicity prediction tools when applied to compensated 
mutations and then propose an alternative machine learning 
approach to assess likely pathogenicity for this particular type of 
mutation. 
 
KEY-WORDS: Compensated pathogenic mutations, CPDs, 
human inherited disease, prediction tools, protein evolutionary 
conservation. 
 
 
INTRODUCTION 
It is almost a truism that the degree of evolutionary conservation of 
an amino acid residue reflects the structural and/or functional 
importance of that residue. Thus, when a missense mutation occurs 
in an amino acid residue that is highly conserved evolutionarily, 
purifying selection tends to act so as to prevent the deleterious 
allele from attaining a high frequency in the population. It is not 
unreasonable to expect that mutations which are disease-causing in 
human would also be deleterious in evolutionarily closely related 
4 
species. However, this expectation has been challenged by the 
realization that there are numerous examples where human mutant 
alleles correspond to the wild-type alleles in other mammalian 
species 1-7. Such mutations have become known as compensated 
pathogenic deviations (CPDs) following their original designation 
5
,  because it is assumed that the apparently benign nature of these 
missense mutations in non-human species is due to the co-
existence of other amino acid substitutions that compensates for 
their otherwise pathogenic outcomeconsequences. Among those 
human mutant residues corresponding to the wild-type residue in 
mouse 5 are an Ala53Thr substitution at the α-synuclein (SNCA) 
locus reported to be associated with familial Parkinson disease 8; 
the BRCA1-Leu892Ser and BRCA2-Val211Ala mutations 
associated with breast cancer; ADA-Arg142Gln causing severe 
combined immunodeficiency, and two mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR-Phe87Leu 
and CFTR-Val754Met) gene underlying cystic fibrosis. Another 
interesting CPD is EIF2B5-Arg113His, the most common lesion 
associated with leukoencephalopathy with vanishing white matter 9 
which corresponds to the wild-type allele in the genomes of both 
rat and mouse 4.  
When the genome sequence of the rhesus macaque was released 3, 
further examples of CPDs were identified. Among them were 
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Tyr356His and Ile164Thr at the phenylalanine hydroxylase (PAH) 
responsible for the most common human inborn error of 
metabolism (phenylketonuria) and Arg40His at the X-linked 
ornithine transcarbamylase (OTC) locus. Although the OTC-
Arg40His replacement leads to the cytosolic degradation of the 
human enzyme precursor 10, abnormal levels of ammonia were not 
evident in simian plasma. Moreover, no abnormal levels of 
phenylalanine were detected in macaque 3 reinforcing the notion 
that these mutations are only deleterious on the human genetic 
background. Intriguingly, a different OTC mutation (Thr125Met) 
associated with fatal hyperammonemia 11 was found to correspond 
to the wild-type allele in chimpanzees 1,12,13. Among the CPD 
mutations identified through a comparison with the recently 
reported mountain gorilla genome 6 were NPC1-Asn961Ser that 
leads to Niemann-Pick disease C and GPAM-Thr447Met 
associated with Complex I deficiency.   
Finally, two mutations associated with ciliopathies, the BBS4-
Asn165His and the RPGRIP1L-Arg937Leu substitutions 
associated with Bardet-Biedl and Meckel-Gruber syndromes, 
respectively, constitute the wild-type alleles in the genomes of 
several vertebrates 7. The same study reported a de novo mutation 
(BTG2-Val141Met) in which the disease-associated variant 
6 
(Met141) corresponded to the wild-type allele in more than 50 
vertebrate species. 
At this stage, it is important to mention that these are examples of a 
more general phenomenon that affects involves about at least 4% 
of all known missense mutations causing human inherited disease 
(see Materials and Methods section). In practice, this proportion 
almost certainly represents a conservative estimate because there is 
an intrinsic ascertainment bias against the recognition and 
reporting of CPDs because such mutations, by their very nature, 
are often predicted to be benign. This bias is exacerbated in the 
context of next generation sequencing (NGS) where the 
inappropriate exclusion of CPDs from further consideration 
constitutes an unfortunate natural consequence of the filtering and 
prioritization of the very large numbers of variants generated. It 
follows that we need to take urgent steps both to assess the scale of 
this problem and to take appropriate remedial action.  
Therefore, iIt is important obviously vital that bioinformatic 
predictionve tools can make accurate predictions when trying to 
assess the pathogenic impact of a putative compensated mutation. 
Because sSome of the existing tools have already proven to been 
shown to fail make incorrectthe  predictions in the case of few 
experimentally validated pathogenic mutations 7., Here, we 
demonstrate, in a larger sample of CPDs, their reduced 
7 
performance of existing tools to predict the deleterious impact of 
CPDs when found as disease-associated variants in humans. 
Further, we present the prototype of a CPD-specific predictor that 
successfully outperformed currently available tools in terms of the 
prediction of the deleterious impact of these mutations in humans.  
 
MATERIALS AND METHODS 
 
Detection of CPDs in mammalian species  
To identify the amino acid positions where a deleterious human 
mutation constitutes the wild-type residue in a non-human 
mammalian species, herein referred to as a CPD 5, we employed 
mutation data from the Human Gene Mutation Database (HGMD; 
http://www.hgmd.org; 52,765 disease-causing missense mutations, 
annotated as DMs; July 2013) to screen 1-to-1 orthologous 
mammalian protein sequences annotated at the Ensembl Genome 
Browser (http://www.ensembl.org;  release 73) 14. Data from a 
total of 39 mammalian species (35 placental, 3 marsupials and 1 
monotreme) were available and sequences were automatically 
retrieved and submitted through a series of stringent filters before 
being considered for subsequent analysis. Whenever more than one 
sequence matched the gene symbol used in the search (due to 
redundancy caused by for example, alternatively spliced isoforms), 
8 
a pairwise alignment with the human reference sequence was 
performed and the sequence retained was that which had the 
highest degree of identity with its human counterpart. In order to 
avoid highly incomplete sequences, we calculated the pairwise 
identity to the human sequence and retained only those that were at 
least 50% identical to the human ortholog. The orthologous 
sequences that passed these filters were then used in the 
identification of CPDs by comparing the aligned sequences. For all 
the cases where a CPD was identified, we applied a strategy 
similar to  that previously documented 5 viz. screening a flanking 
window of five amino acid residues upstream and downstream of 
the putative CPD site and retaining only those CPDs with no more 
than four differences with respect to the human sequence within 
the flanking region. Missense mutations at the initiator methionine 
residue were removed from the analysis. This strategy allowed the 
identification of 1,964 CPDs in a total of 684 protein-coding genes 
[LUISA: Are you going to make these data available online? I 
think we may be required to do this. If not, you should maybe say 
‘data available on request’], a figure which corresponds to about 
3.,7% of all missense mutations analysed. All the alignments were 
performed using ClustalO 1.2.0 (www.clustal.org/omega) 15 and 
other tools were developed locally using GNU/Linux-based 
computers with scripting tools + C language.  
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DM set 
A set of 10,211 disease-causing missense mutations which result in 
an amino acid substitution (AAS) in 2,030 genes was obtained 
from the Human Gene Mutation Database (HGMD) 16. This set of 
disease-causing mutations is representative of datasets that have 
typically been employed in the training and evaluation of a number 
of different bioinformatic prediction tools to identify disease-
causing AAS. In order to allow an unbiased evaluation of 
bioinformatic prediction tools, an unseen test set (not used for 
training) should always be used, otherwise the evaluation 
represents in-sample error rather than out-of-sample error and 
hence is likely to be overly optimistic in terms of prediction 
performance. As some of the prediction tools evaluated here (e.g. 
MetaSVM) either already used, or could have used, HGMD (or 
other similar overlapping datasets e.g. OMIM) either as training 
data or in the development of the prediction method, this DM set 
was selected so as to contain only recently reported (2014 
onwards) disease-causing missense mutations from HGMD. This 
dataset of disease-causing mutations would therefore not therefore 
have been available when the various prediction tools being tested 
were being developed. This set of disease-causing mutations is 
henceforth referred to as the DM set.  
10 
 
SNP set 
As a negative control,   a set of 2,174 putatively ‘neutral’ common 
missense SNPs (MAF ≥ 0.4) in 1,640 genes from the NHLBI 
ESP6500 Exomes (http://evs.gs.washington.edu/EVS/) was 
compiled. This set is henceforth referred to as the SNP set. 
 
Performance evaluation of bioinformatic prediction tools used 
to identify disease-causing mutations 
 
Numerous different prediction methods to identify disease-causing 
or functional variants have been developed. The four selected here 
(SIFT 17, Mutation Assessor 18, PROVEAN 19 and MetaSVM 20) 
were selected on the grounds that they are commonly used (e.g. 
SIFT) or represent a different approach to the classification 
problem [e.g. MetaSVM, an ensemble approach using population 
frequency data and the scores from 10 other prediction methods 
(SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, GERP++, 
MutationTaster, Mutation Assessor, FATHMM, LRT, SiPhy, 
PhyloP)]. Prediction scores for the CPD, DM and SNP sets (where 
available) were then obtained from dbNSFP (version 3.2c) 20.  As a 
means to evaluate performance for each of the four bioinformatic 
prediction methods, receiver operating characteristic (ROC) curves 
11 
and the area under the ROC curve (AUC) were calculated for the 
CPD set versus the SNP set and the DM set versus the SNP set. 
 
Feature subset ranking 
In order to evaluate discriminative features or attributes 
(commonly used to identify disease-causing mutations) in the 
context of CPDs, an array of features relating to the AAS (e.g. 
solvent accessibility) were derived from SNVBox 21 (Table 1). 
Related features were then grouped into seven different subsets 
(Amino acid based, Exon based, Genomic MSA, Protein MSA, 
Protein structure, Regional protein composition and annotated 
functional sites) (Table S1). For more details, please refer to 
SNVBox 21. The prediction performance of each feature subset 
(e.g. Eexon based features) was evaluated using cross-validation 
and a linear support vector machine for two different datasets 
(CPD&SNP, DM&SNP). This allowed us to rank how informative 
each feature subset was for identifying CPDs and also for 
identifying disease-causing mutations. 
 
A machine learning approach to assess the pathogenicity of 
potential CPDs  
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Current methods to assess the pathogenicity of potential disease-
causing mutations have not been specifically developed or 
evaluated in the context of CPDs. Although they do demonstrate 
some utility in the functional assessment of CPDs, we set out to 
develop a novel prototype CPD-specific predictor. Using the 
features employed in this study (Table S1), two different Random 
Forest classification models were built: the first, termed the 'CPD 
trained model', was trained using the CPD (positive examples) and 
SNP (negative examples) sets. The second model, termed the 'DM 
trained model', was trained using the DM set as positive examples 
and the SNP set as negative examples. The DM trained model also 
excludes any features derived from multiple sequence alignments 
(MSA). The area under the ROC curve (AUC) was then calculated 
for each model (CPD trained model and DM trained model). We 
also employed standard benchmarking statistics (Table S2) to 
evaluate performance such as the true positive rate (sensitivity), the 
false positive rate and the Matthew’s Correlation Coefficient 
(MCC) 22. The MCC was employed since it represents one of the 
best available measures of prediction quality. It returns a value 
between −1 and +1; a coefficient of −1 represents the worst 
possible prediction, 0 a random prediction and +1 a perfect 
prediction. 
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RESULTS AND DISCUSSION 
 
How accurately are CPDs predicted by current bioinformatics 
tools? 
Due Owing to their occurrence in multiple sequence alignments 
(MSA), there may well be a tendency for CPDs to evade detection 
by the predictive tools commonly used to evaluate the functional 
impact of human missense variants, simply because the mutant 
residues in question are tolerated in other species. Most predictive 
methods rely to some extent on the degree of evolutionary 
conservation of the mutated residue but, when a mutant residue 
occurs as the wild-type allele in one or more orthologs, its 
pathogenicity in a human context may not be readily predictable. 
Thus, for example using three widely used predictive tools, 
PolyPhen 23, SIFT 17 and MutationAssessor 24, Jordan and 
colleagues 7, failed to predict the deleterious effect of three 
compensated mutations (BBS4-Asn165His, RPGRIP1L-
Arg937Leu and BTG2-Val141Met) experimentally demonstrated 
to be pathogenic in human. 
To assess the extent of the ability of existing predictive methods to 
deal with CPDs, we compared a set of more than 10,200 disease-
causing mutations from the HGMD with a set of CPDs and a set of 
neutral missense SNPs (MAF≥0.4) (Figure 1). The results showed 
14 
that all four bionformatic prediction tools tested here exhibited 
reduced prediction performance (-24.2% to -8.5% AUC) in relation 
to CPDs as compared to disease-causing mutations. Of the four 
tools analysed, SIFT exhibited the largest reduction in prediction 
performance (-24.2%). MetaSVM, a consensus of scores from 10 
different tools (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, 
GERP++, MutationTaster, Mutation Assessor, FATHMM, LRT, 
SiPhy, PhyloP) and the maximum frequency observed in the 1000 
Genomes populations, outperformed all other tools in terms of 
identifying CPDs, suggesting that an ensemble approach could be 
useful in classifying CPDs. 
Evaluation of features commonly used to identify disease-
causing AAS 
In order to perform an evaluation in the context of CPDs, the 
discriminatory power of groups of related features (e.g. structural 
features) used to distinguish disease-causing missense mutations 
from neutral polymorphic missense variants (Table S1) was 
computed using 10-fold cross- validation with a linear support 
vector machine (Figure 2). The most informative feature subsets 
discriminating disease-causing mutations from common putatively 
neutral polymorphisms (SNP set) were derived from MSA (95% 
AUC for genomic MSA and 81% AUC for protein MSA; Figure 2 
- DM set). These MSA- derived features (genomic and protein 
15 
MSA) also demonstrated the largest reduction in performance (-
20% in AUC) when used to discriminate between the CPDs and 
the SNP set (as compared to the DM versus the SNP set; Figure 2 - 
CPD set). 
 
A machine learning approach to evaluate potential CPDs 
We next developed two different machine learning approaches to 
assess the pathogenicity of potential CPDs using the features 
indicated in Table S1 (see Materials and Methods section). The 
CPD trained model (AUC=86.21%) outperformed the DM trained 
model (with no MSA features) by over 10% based on the AUC 
(Table S2, Figure 3). Both models shared similar false positive 
rates with the DM trained model exhibiting reduced sensitivity (-
23.2%) as compared to the CPD trained model. In the context of 
identifying CPDs, the CPD model developed here outperformed all 
existing bioinformatic prediction methods evaluated in this study, 
indicating utility in developing a specific CPD predictor. 
 
In conclusion, the scale of the compensated mutation phenomenon 
is such that a significant proportion of pathogenic human missense 
mutations (a minimum of 3.,7%) are found as the wild-type allele 
in at least one of the other mammalian species here analysed here. 
In terms of evaluating the pathological impact of these mutations, 
16 
traditional approaches suffer from the serious drawback of relying 
upon the evolutionary conservation score between homologous 
proteins irrespective of the influence of genetic variation at other 
amino acid positions. Here we demonstrate the poor performance 
of established mutation prediction tools to assess the pathological 
significance of CPDs and show that the development of new tools 
should yield an increase in prediction accuracy by avoiding the 
information provided by the MSA features. The in silico 
assessment of pathogenesis for novel CPDs that result from 
identified by whole exome/genome NGS studies currently requires 
a different protocol from that employed for the bulk of non-
compensated mutations. We propose a two-stage analysis whereby 
whole exome/genome data should first be screened for potential 
CPDs (using the strategy employed in this study and in others 5 to 
identify missense variants where the mutant amino acid represents 
the wild-type amino acid in another mammalian species). A 
method such as the novel CPD prediction tool developed here 
could then be applied to identify any high confidence CPD 
candidates for further analysis. Adoption of a CPD-specific 
protocol could help to reduce avoid the mis-classification of a 
sizable proportion of pathogenic missense mutations as benign. 
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Figures  
 
Figure 1. Performance evaluation of four different bioinformatic tools (SIFT, 
Mutation Assessor, PROVEAN and MetaSVM) used to identify disease-causing 
mutations. Each bioinformatic tool was evaluated on compensated pathogenic 
deviations (CPDs) and disease-causing mutations (DMs). Receiver operating 
characteristic (ROC) curves and the area under the ROC curve (AUC) were 
calculated for each mutation dataset (CPD & DM) with a different prediction 
tool. An AUC of 100% would represent a perfect predictor, whereas an AUC of 
50% would represent a prediction tool making only random predictions (denoted 
by the black diagonal line). Note: MetaSVM is an ensemble prediction method 
based on 10 other prediction tools. 
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Figure 2. Evaluation of different groups of commonly used features (feature 
subset ranking) used to identify disease-causing amino acid substitutions (AAS). 
Each feature subset is then evaluated (10-fold cross-validation using a linear 
support vector machine) in the context of (i) discriminating between CPDs and 
common polymorphisms (CPD versus SNP set), (ii) discriminating between 
disease-causing mutations (DMs) and common polymorphisms (DM versus SNP 
set). The AUC of the ROC curve was then calculated for each feature subset; 
features employed in each subset are shown in Table 1. As a control, a random 
feature was computed for each training example and the AUC of the ROC 
calculated. 
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Figure 3. Performance evaluation for the identification of CPDs by means of a 
ROC curve using 10-fold cross- validation of the two Random Forest prediction 
models developed in this study. The first model, termed the 'CPD trained model', 
was trained using the CPD and SNPs sets employed in this study (ROC shown 
in red). The second model, the 'DM trained model', was trained using disease-
causing mutations (DM and SNP sets) but excludes any features derived from 
multiple sequence alignments (MSA). ROC shown in blue. The area under the 
ROC curve (AUC) was then calculated for each model (CPD trained model and 
DM trained model). An AUC of 100% would represent a perfect predictor, 
whilst whereas an AUC of 50% represents would correspond to a prediction tool 
making random predictions (represented by the black diagonal line). 
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Supplementary files: 
 
Table S1. Summary of features commonly used used in 
bioinformatic tools to identify deleterious amino acid substitutions 
(AAS). Features were obtained using the SNVBox software for all 
datasets (CPD, DM and SNP sets). The descriptions of features 
were taken from the SNVBox User Manual 
(http://karchinlab.org/apps/snvbox/userdoc.pdf); for more details 
please refer to SNVBox [6]. [LUISA: I think the reference you mean 
is probably 21] 
 
Feature name Feature subset Description 
AA Hydrophobicity Amino acid features Change in hydrophobicity as a 
result of the AAS 
AA Charge Amino acid features Change in formal  charge as a 
result of the AAS 
AA Volume Amino acid features 
Change in  residue  volume as a 
result of the AAS (cubic  
Angstroms) 
AA Polarity Amino acid features Polarity change  as a result of the AAS 
AA Matrix Amino acid features 
Amino  acid  substitution  scores  
from  BLOSUM  62, PAM250, 
EX, Venkatarajan and Braun 
matrix & Miyazawa-Jernigan 
contact energy matrix 
25 
AA Transition Amino acid features 
Frequency of  transition  
between  two  neighbouring  
amino acids based  on  all  
human  proteins  in SwissProt 
AA Grantham score Amino acid features 
The Grantham  distance  from  
reference  to  mutation  amino 
acid residue 
AA Frequencies Amino acid features 
Frequency of AAS type  (e.g.  
alanine  to  glycine)  in  HGMD 
(2003), HapMap (dbSNP build 
129) and COSMIC  (release 38) 
Exon Conservation Exonic features 
Entire  exon conservation 
computed from a 46-way 
genomic vertebrate alignment 
Exon SNP Density Exonic features 
Number of  HapMap verified  
SNPs in the exon where the 
mutation is located divided by 
the length of the exon 
Genomic multiple sequence 
alignments (MSA) Genomic MSA 
Features calculated from 46-way 
genomic vertebrate alignments, 
which includes Shannon entropy 
and the Kullback-Leibler 
divergence 
Protein multiple sequence 
alignments (MSA) Protein MSA 
Features calculated from 
multiple sequence alignment of 
diverse homologous proteins. 
Features computed include the 
Shannon entropy and Kullback-
Leibler divergence 
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Solvent accessibility 
Protein structure 
Prediction that wild-type residue 
is buried, partially buried or 
exposed in terms of solvent 
accessibility  
Secondary structure 
Protein structure Prediction that wild-type residue is helix, loop or strand 
Protein stability 
Protein structure 
Prediction of the degree to which 
the wild-type residue contributes 
to protein stability e.g. highly 
stabilizing 
Backbone flexibility  
Protein structure 
Prediction of the flexibility of 
the backbone of the wild-type 
residue 
Protein composition Regional protein 
composition 
Features based on regional 
amino acid composition in a 15-
amino-acid-residue window 
centred on the AAS 
UniProt annotations of 
human proteins Annotated functional sites 
Includes functional sites 
annotated by UniProt, including 
binding sites (e.g. DNA, RNA, 
lipid, metal, carbohydrate, 
calcium), catalytic sites, sites of 
post-translational modifications, 
localization signals, disulphide 
bonds, protein-protein 
interaction sites 
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Table S2. Performance benchmarks for the identification of CPDs based 
on the two machine learning models developed in this study. The first 
model, termed the 'CPD trained model', was trained using the sets of 
CPDs and common SNPs employed in this study (CPD and SNP sets). 
The second model, the 'DM trained model' was trained using disease-
causing mutations and common SNPs (DM and SNP sets) but excludes 
any features derived from multiple sequence alignments (MSA). The 
Random Forest machine-learning algorithm was employed, and 
evaluation was performed using a variation of 10-fold cross-validation 
whereby the positive evaluation set in each fold comprised unseen 
examples from the CPD set for both models (DM trained model and CPD 
trained model). TPR = true positive rate (sensitivity). FPR = false 
positive rate. MCC = Matthew’s Correlation Coefficient; an MCC of −1 
represents the worst possible prediction, 0 a random prediction and +1 a 
perfect prediction. 
Dataset TPR FPR MCC AUC of ROC 
CPD trained 
model 78.05 21.75 0.56 86.21 
DM trained 
model (no MSA 
features) 
54.84 21.98 0.34 75.10 
 
 
 
 
 
